<DOC>
	<DOC>NCT01187381</DOC>
	<brief_summary>This single arm observational study will assess the duration and safety of treatment with Herceptin (trastuzumab) in routine clinical practice in patients with early or metastatic HER2-positive breast cancer. Data will be collected from female patients treated with Herceptin according to the Summary of Product Characteristics and local protocols. Duration of observation for each patient is from therapy initiation until permanent discontinuation for any cause.</brief_summary>
	<brief_title>An Observational Study of the Mean Duration of Herceptin (Trastuzumab) Treatment in Patients With Early or Metastatic HER2-positive Breast Cancer (HERODOT)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patients, &gt;/= 18 years of age HER2positive breast cancer Treated with Herceptin in accordance with Summary of Product Characteristics and local protocols Written informed consent to data collection Any contraindication to Herceptin Clinically relevant cardiovascular disorder or disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>